Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progressionHELIYONIF3.62022-04-0121OAAI
Delayed haemolysis after IV artesunate therapy for P. falciparum infectionTRAVEL MEDICINE AND INFECTIOUS DISEASEIF4.72022-01-011PRE
Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection (vol 2, dlaa071, 2020)JAC-ANTIMICROBIAL RESISTANCEIF3.32020-12-080OAAI
Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infectionJAC-ANTIMICROBIAL RESISTANCEIF3.32020-08-2558OAAI
Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycinBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32020-08-0225OAAI